The Discounted Cash Flow (DCF) valuation of Halozyme Therapeutics Inc (HALO) is 64.53 USD. With the latest stock price at 48.00 USD, the upside of Halozyme Therapeutics Inc based on DCF is 34.4%.
| Range | Selected | |
| WACC / Discount Rate | 8.0% - 10.3% | 9.1% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | 43.65 - 115.37 | 64.53 |
| Upside | -9.1% - 140.3% | 34.4% |